On March 31, 2021 Hemispherian AS ("Hemispherian" or the "Company"), a Norwegian preclinical pharmaceutical company focused on epigenetic therapeutics for the treatment of cancer, reported that the United Kingdom Intellectual Property Office (UKIPO) has granted the company’s first patent, which covers a family of small molecule drugs effective against a broad range of cancers (Press release, Hemispherian, MAR 31, 2021, View Source [SID1234578117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent covers the use of compounds from the GLIX family in cancer treatment or prevention alone or in combination with one or more further anticancer agents. It was filed in February 2019 and it will therefore offer exclusivity until February 2039. This new patent is owned by Hemispherian and all the inventors are now part of the executive team of the Company.

"We are extremely pleased that the UKIPO has granted the patent. This is the culmination of a decade of academic research and development. This newly granted patent is a cornerstone in Hemispherian’s IP strategy aiming to produce a range of cancer drugs targeting an entirely new mechanism of action."